This trial was conducted to study the potential for hypersensitivity symptoms at the time of
initial exposure to sugammadex and upon repeat exposure, since it was unknown whether the
frequency or severity of hypersensitivity symptoms may worsen at repeat exposure over a
prolonged period.
In total 450 participants (all healthy subjects) were to be randomized to receive one of
three study treatments: three repeated doses of either sugammadex 4 mg/kg, sugammadex 16
mg/kg, or placebo. Participants were to receive one dose of study treatment on Day 8, Day 36,
and Day 78 of the study in order to determine the safety of each treatment dose.